Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Expected to Reach USD 89.6 Million by 2034 at a 3.7% of CAGR

ESR1 Mutated Metastatic Breast Cancer Diagnostics Market

The global ESR1 mutated metastatic breast cancer diagnostics market is projected to grow steadily, expanding from USD 63.4 million in 2024 to USD 89.6 million by 2034, representing a year-over-year growth rate of 4.0%. This growth reflects a compound annual growth rate (CAGR) of 3.7% over the forecast period.

Demand for ESR1 mutation diagnostics in metastatic breast cancer is on the rise due to the increasing focus on personalized and precision oncology. Advances in diagnostic technology and heightened awareness of mutation-specific cancer therapies are further driving market expansion. The ESR1 mutation, a critical biomarker in metastatic breast cancer, enables oncologists to tailor treatments effectively, enhancing patient outcomes and supporting long-term disease management.

This projected growth highlights substantial opportunities for diagnostics companies, research institutions, and healthcare providers focused on innovative diagnostic solutions that enable targeted therapies in the fight against metastatic breast cancer.

The market value for ESR1 mutated metastatic breast cancer diagnostics was around 0.9% of the global breast cancer diagnostics market. However, this value share is expected to increase significantly during the forecast period, owing to factors like:

• Rising prevalence of metastatic breast cancer globally
• Growing awareness about breast cancer and metastatic breast cancer testing
• Increasing adoption of precision diagnostics for metastatic breast cancer detection
• Surging interest in breast cancer precision medicine
• Advancements in ESR1 gene mutation diagnostics
• Continuous research in ESR1-related diagnostics and therapeutics
• Increasing number of breast cancer awareness programs

ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Trends

• Growing need for advanced breast cancer mutation diagnostics
• Rising popularity of breast cancer biomarker testing
• Shift towards personalized medicine and increasing importance of ESR1 testing in precision medicine
• Surging preference for liquid biopsies as a gold standard diagnostic tool for cancer detection
• Ongoing advancements in molecular diagnostics like next-generation sequencing (NSG) and polymerase chain reaction (PCR)

Competitive Landscape

Partnerships and collaborations are a priority for leading ESR1 mutated metastatic breast cancer diagnostic kit manufacturers. They are also investing rigorously in research and development to introduce novel breast cancer diagnostic solutions.

Recent Developments in the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market:

• In June 2023, NeoGenomics, Inc., a leading provider of oncology testing and global contract research services, announced that its RaDaR® assay, a personalized liquid biopsy for recurrence detection and minimal/molecular residual disease, obtained first pan-cancer commercial coverage by Blue Shield of California.
• In December 2022, Guardant Health, Inc., a leading precision oncology company, collaborated with AstraZeneca to pursue the development, regulatory approval, and commercialization of the Guardant360® CDx blood test as a companion diagnostic to identify patients with ESR1-mutated metastatic breast cancer.

Key Companies Profiled

APIS Assay Technologies; Illumina, Inc.; GENCURIX; RainSure Scientific; NeoGenomics Laboratories; Sysmex Corporation; ASURAGEN, INC.; Guardant Health

A Full Report Overview

ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Segmentation

By Test Type:

• NGS Based
• PCR Based

By Sample Type:

• Tissue
• Plasma

By End-user:

• Hospital Associated Labs
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes

By Region:

• North America
• Latin America
• East Asia
• South Asia & Pacific
• Western Europe
• Eastern Europe
• Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube